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Abstract: While accounting for only 1% of solid organ malignancies (9% in women), thyroid 
carcinoma is the most common malignancy of the endocrine system. Although most patients 
have a favorable prognosis, over 1,500 people will die from thyroid carcinoma each year. The 
spectrum of disease types range from papillary thyroid cancer, which is a well-differentiated 
indolent tumor, to anaplastic carcinoma, a poorly differentiated fulminant cancer. With advances 
in diagnostic methods, surgical techniques, and clinical care of patients with thyroid carcinoma, 
the current management of thyroid cancer demands a multidisciplinary approach. The majority 
of patients with well-differentiated thyroid carcinoma of follicular cell origin are cured with 
adequate surgical management; however, some thyroid malignancies such as medullary thyroid 
carcinoma (MTC) or poorly differentiated thyroid carcinomas frequently metastasize, precluding 
patients from a curative resection. As such, novel palliative and therapeutic strategies are needed 
for this patient population. Here, we explore the current management of thyroid carcinoma, 
including surgical management of the primary tumor, lymph node disease, and locoregional 
recurrence. Likewise, we explore the application of current molecular techniques, reviewing 
nearly two decades of data that have begun to elucidate critical genetic pathways and therapeutic 
drug targets which may be important in speciﬁ  c thyroid tumor types.
Keywords: thyroid carcinoma; vascular endothelial growth factor receptor (VEGFR); epidermal 
growth factor receptor (EGFR); RET tyrosine kinase (RTK); glycogen synthase kinase-3β 
(GSK-3β)
Background
Thyroid carcinoma is the most common cancer of the endocrine system (Hundahl et al 
1998); in fact, approximately 33,550 patients are diagnosed with thyroid cancer annually 
in the United States, leading to an estimated 1,530 deaths per year (American Cancer 
Society 2007). While there are four main varieties of thyroid carcinoma, for purposes 
of clinical management of the patient, thyroid cancer is generally divided into three 
categories: well-differentiated thyroid cancer of follicular cell origin, medullary thyroid 
carcinoma (MTC), and undifferentiated or anaplastic cancer. Differentiated thyroid 
carcinomas are believed to arise from the follicular epithelial cells and account for nearly 
94% of all thyroid malignancies (Sherman 2003). Generally, differentiated thyroid 
cancers include papillary carcinoma (PTC), follicular carcinoma (FC), and Hürthle 
cell carcinoma (HCC). MTCs, neuroendocrine tumors involving the parafollicular 
C cells derived from the neural crest, comprise approximately 5% of thyroid cancers 
(Sherman 2003; Hanks 2004; Chen et al 1998b). Less common, poorly differentiated 
thyroid cancers tend to be more aggressive, metastasize earlier, and portend a generally 
worse prognosis. The most common of these, anaplastic thyroid carcinoma, is thought 
to develop from the dedifferentiation of the differentiated type (Sherman 2003).
In a national cancer database report on 53,856 cases of thyroid carcinoma treated in 
the US from 1985 to 1995, Hundahl et al (1998) reported that 10-year overall relative Therapeutics and Clinical Risk Management 2008:4(5) 936
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survival rates for patients with papillary, follicular, Hürthle 
cell, and medullary carcinoma was 93%, 85%, 76%, and 75%, 
respectively. Patients with undifferentiated/anaplastic carci-
noma (only 1.7% of the 53,856 cases) had a dismal prognosis, 
with only 14% surviving 10 years. Age at the time of diagno-
sis appears to be the most important independent prognostic 
variable, as the prognosis for differentiated thyroid carcinoma 
is better for patients younger than 40 years (Cady et al 1979; 
Sanders and Cady 1998; Dean and Hay 2000; Clark 1985); 
evidence suggests this age cutoff may extend to 50 years in 
women with no other negative prognostic factors. Likewise, 
size less than 4 cm and absence of distant metastasis at the 
time of initial treatment are important independent positive 
predictors of survival (Cady et al 1979; Sanders and Cady 
1998; Dean and Hay 2000; Clark 1985).
Well-differentiated thyroid carcinoma is a unique, het-
erogeneous disease; unlike the majority of epithelial cancers, 
differentiated thyroid cancer patients do extremely well, 
with few having recurrences and even fewer dying from the 
disease. As a result, the best treatment modality for patients 
with well-differentiated thyroid carcinoma is a source of con-
troversy. Tailoring treatment modalities to the patient’s risk 
of recurrence or death is of paramount importance. Currently, 
several treatment modalities (ie, thyroidectomy, radioiodine 
ablation, and thyroid-stimulating hormone [TSH] suppres-
sive therapy) are widely used in the treatment of thyroid 
carcinoma; however, recent data suggest that in spite of this 
multimodal approach to cancer care, relative survival rates 
have only minimally improved in the last several decades 
Sherman 2003; Colonna et al 2006). Of equal importance, 
chemotherapy and external beam radiation are minimally 
effective in the treatment of aggressive thyroid cancers 
(Haugen 1999), highlighting a need for the development of 
novel, effective therapies for thyroid carcinoma. Here, we 
review current multimodal therapies used in the treatment of 
thyroid carcinoma, and we discuss the recent efforts to iden-
tify novel chemotherapeutic targets which may be important 
in the treatment of this disease.
Current therapeutic modalities
With advances in diagnostic methods, surgical techniques, 
and clinical care of patients with thyroid carcinoma, the 
management of well-differentiated thyroid cancer demands 
a multidisciplinary approach. However, while multimodality 
therapy has been the cornerstone of treatment for most thy-
roid cancers, there are little prospective data to support this 
approach. Decisions about the best treatment for individual 
patients with thyroid carcinoma are often controversial and 
supported only by retrospective analyses. In an attempt to 
direct diagnosis and treatment decisions in patients with 
thyroid cancer, several guidelines for the current manage-
ment of thyroid carcinoma have been offered (Udelsman 
and Chen 1999; Task Force TC 2001; Thyroid Carcinoma 
Task Force 2001; Kendall-Taylor 2003; Cooper et al 2006; 
Perros 2007; British Thyroid Association and Royal College 
of Physicians 2008).
Primary surgical management
Thyroidectomy is the preferred initial management of PTC, 
FC, MTC, HCC, and isolated metastases to the thyroid 
gland (Udelsman and Chen 1999; Chen et al 1999; Cheema 
et al 2006; Greenblatt et al 2007). In undifferentiated or 
anaplastic thyroid carcinoma, complete surgical resection 
is frequently not possible and there is no effective systemic 
therapy (Mazzaferri 2007); however, thyroidectomy may be 
utilized to make a deﬁ  nitive diagnosis or palliate symptoms of 
airway compromise (Udelsman and Chen 1999; Mazzaferri 
2007; Lang and Lo 2007). Interestingly, though the outcomes 
for anaplastic thyroid carcinoma (ATC) are dismal, recent 
data suggest that complete surgical resection combined with 
radiation and chemotherapy (doxorubicin), in aggressive 
multimodal therapies, offers the best outcome in patients 
with ATC (Udelsman and Chen 1999; Sugino et al 2002; 
Lam et al 2000; Tennvall et al 1994).
The extent of thyroidectomy for well-differentiated 
thyroid carcinoma is controversial because no prospective 
randomized trial could be performed; however, it is clear 
that any surgery less than thyroid lobectomy has no role 
in the management of differentiated thyroid cancer. Based 
on several large retrospective reports, total thyroidectomy 
is the preferred initial surgical procedure for most patients 
with clinically signiﬁ  cant (tumors 10 mm in diameter), 
well-differentiated thyroid cancer (Mazzaferri and Jhiang 
1994; Chen and Udelsman 1998; Hay et al 1998; Katoh et al 
1992; Taylor et al 1989). Recently, Bilimoria et al published 
the largest study on PTC to date (Bilimoria et al 2007); in a 
review of over 50,000 patients, bilobar resection was found 
to be associated with improved survival compared to thyroid 
lobectomy. This represents the only published report of a 
survival beneﬁ  t to bilobar resection and has helped to answer 
the question over extent of surgery in patients with clini-
cally signiﬁ  cant PTC. The rationale for total thyroidectomy 
in the treatment of well-differentiated thyroid carcinoma is 
lent support by the following points: total thyroidectomy 
improves the effectiveness of radioactive iodine (131I) ablation 
therapy, a signiﬁ  cant factor shown to prolong survival and Therapeutics and Clinical Risk Management 2008:4(5) 937
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lower recurrence rates (Mazzaferri and Jhiang 1994; Chen 
and Udelsman 1998; DeGroot et al 1990; Krisnamurthy and 
Blahd 1977); the speciﬁ  city of serum thyroglobulin concen-
trations as a tumor marker are highest with resection of as 
much thyroid tissue as is safely possible (Sherman 2003; 
Ozata et al 1994); total thyroidectomy reduces the recur-
rence rate in patients with well-differentiated thyroid cancer 
(DeGroot et al 1990; Mazzaferri and Young 1981; Mazzaferri 
et al 1977), speciﬁ  cally since 5%–10% of recurrences of PTC 
after lobectomy arise in the contralateral lobe (Sherman 2003; 
Silverberg et al 1970); and total thyroidectomy, in the hands 
of an experienced surgeon, has been shown to have equivalent 
morbidity and mortality rates as the unilateral (lobectomy) 
procedure (Chen et al 1998a; Clark 1982).
Most current guidelines for the management of well-
differentiated thyroid carcinoma suggest that patients with 
PTC more than 10 mm in diameter or with high-risk PTC or 
FTC (extrathyroidal extension of disease, bilateral or multicen-
tric PTC, distant metastatic disease, or prior history of ionizing 
radiation to the neck) should undergo near-total or total thy-
roidectomy (Sherman 2003; British Thyroid Association and 
Royal College of Physicians 2008; Task Force TC 2001). It is 
generally accepted that thyroid lobectomy may be employed 
for patients with low-risk, occult PTC (10 mm in diameter), 
as the risk of death from a non-multicentric, 10mm lesion is 
quite low (Udelsman and Chen 1999; Mazzaferri and Jhiang 
1994). Conversely for FTC, although the absence of multi-
centric disease and small tumor size (10 mm in diameter) 
may argue against total thyroidectomy for management of 
the primary tumor, total thyroidectomy is typically recom-
mended to allow for better outcomes with 131I ablation therapy 
(Sherman 2003; British Thyroid Association and Royal Col-
lege of Physicians 2008).
As ultrasonography and ﬁ  ne-needle aspiration biopsy 
for thyroid lesions have recently increased in preva-
lence, the diagnosis of papillary thyroid microcarcinoma 
(PTMC) – thyroid carcinomas of less than 10 mm or less 
in maximum diameter (Hedinger et al 1988) – is becoming 
more common. The “ideal” therapeutic approach for patients 
with PTMC remains a subject of debate among endocri-
nologists and surgeons (Küçük et al 2007). While previous 
studies have shown that PTMC may account for nearly 30% 
of PTC cases, whether these microcarcinomas grow and 
become clinically apparent or life threatening for patients 
is unknown. In a recent observational trial of 162 patients, 
Ito et al (2003) showed that only 10.2% of low-risk PTMC 
enlarged by more than 10 mm during 5 years of follow-up 
and only 1.2% of patients developed lymph node metastases 
in the lateral compartments; more than 70% of tumors either 
did not change or decreased in size compared to the initial 
size at diagnosis, suggesting that PTMC may be observed 
as long as the tumor shows no progression. Ito et al further 
suggested that “if surgical treatment is performed for low-
risk [PTMC], prophylactic modiﬁ  ed radical neck dissection 
is not necessary, and lobectomy (with isthmusectomy) and 
central node dissection is adequate if the tumor is located 
only in one lobe” (Ito and Miyauchi 2007).
Management of lymph node disease
While only 35% of patients with PTC have cervical or 
mediastinal lymph node metastases grossly detectable at 
the time of initial surgery (Sherman 2003), the presence of 
microscopic regional metastases to nodes is not uncommon. 
In fact, when prophylactic lymphadenectomy was performed 
on all patients with PTC in the early years of surgical man-
agement, up to 90% were found to have microscopic lymph 
node metastases (Udelsman and Chen 1999; Attie et al 1971; 
Frazell and Foote 1955). The presence of micrometastases in 
the cervical lymph nodes, however, has not been shown to 
affect survival (Young et al 1980; Hay et al 1993; Byar et al 
1979; Grebe and Hay 1996). In a review of 1,019 patients 
with differentiated thyroid cancer treated between 1940 
and 1990, Sanders et al noted no signiﬁ  cant difference in 
20-year adjusted survival rate among high-risk patients with 
involved nodes and without involved nodes (58.5% versus 
45.5%, respectively) (Sanders and Cady 1998). Likewise, 
the 20-year adjusted survival rate was not signiﬁ  cantly 
different in low-risk patients both with and without nodal 
involvement (94.6% versus 96.5%, respectively) (Sanders 
and Cady 1998). While a recent meta-analysis of several 
studies conﬁ  rms no relationship between lymph node status 
at presentation and survival, several studies did show an 
increased risk of tumor recurrence (Sherman 2003; Grebe 
and Hay 1996). In a retrospective study, Simon et al (1996) 
showed 51% of patients with differentiated thyroid cancer 
who had a total thyroidectomy alone developed regional 
recurrence, compared with 18% who also had lymph node 
dissection.
Until recently, it has generally been accepted that lymph 
node status in PTC affects only local recurrence rates rather 
than survival. However, the topic has evolved considerably in 
the last several years, as data from a large population-based 
study have demonstrated signiﬁ  cantly higher mortality rates 
for differentiated thyroid cancer with nodal involvement 
(Lundgren et al 2006). When lymph node metastases are 
clinically evident on physical examination or routine cervical Therapeutics and Clinical Risk Management 2008:4(5) 938
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ultrasound, it is generally agreed upon in most centers that 
surgical lymphadenectomy (LND) is the best form of treat-
ment. In fact, many centers, including our own institution, 
have advocated ipsilateral modiﬁ  ed radical neck dissection 
(MRND) as described by Bocca et al (1980, 1984) for clini-
cally evident nodal involvement in the lateral neck to reduce 
the frequency of regional recurrence. Likewise, central neck 
dissection is warranted for PTC with clinically evident or 
pathologically involved nodes in the central compartment of 
the neck (also known as level IV), the region most frequently 
involved with skip metastases (Machens et al 2004; Qubain 
et al 2002).
However, controversy exists regarding the role of routine 
or prophylactic LND in PTC cases where nodal disease is 
not clinically detected (Sywak et al 2006). In a retrospective 
cohort study of nearly 450 patients, Sywak et al have dem-
onstrated that, in PTC, the addition of routine central lymph 
node dissection (CLND) results in lower postablation thyro-
globulin levels and potentially reduces recurrent or persistent 
disease and avoids reoperative surgery. Similarly, through 
an evidence-based meta-analysis of relevant literature, 
White et al (2007) provide levels IV and V data suggesting 
that systematic compartment-oriented CLND may decrease 
recurrence of PTC and likely improves disease-speciﬁ  c 
survival (grade C recommendation). Additionally, limited 
level III data are provided suggesting a survival beneﬁ  t with 
the addition of prophylactic dissection to thyroidectomy 
(grade C recommendation). While the debate will undoubt-
edly continue, at our institution we do not routinely perform 
routine or prophylactic MRND or CLND in the absence of 
clinically evident nodal disease, as there are no convincing 
level I or II data demonstrating the beneﬁ  t of prophylactic 
nodal dissection in these patients with PTC (Udelsman and 
Chen 1999).
Lymph node involvement with FTC is rare; in fact, nodal 
disease is present in less than 13% of patients in most com-
prehensive reviews (Emerick et al 1993). Rather, follicular 
carcinomas have a predilection for hematogenous metasta-
sis, commonly invading blood vessels en route to bone and 
lung. Importantly, the oxyphilic variant of follicular thyroid 
carcinoma (HCC) behaves in a more aggressive fashion than 
well-differentiated FTC and, if malignant, often shows early 
nodal spread (Sherman 2003). Likewise, due to its relatively 
low avidity for radioiodine, HCC is essentially a surgical 
disease. Therefore, nodal disease from all differentiated 
thyroid carcinomas of follicular cell origin (PTC, FTC, and 
HCC) should be treated with aggressive surgical resection of 
clinically evident nodal disease; that is, CLND is advocated 
for clinically evident or pathologically proven nodal disease 
in the central neck while ipsilateral MRND is advocated for 
obvious disease in the lateral neck.
Unlike well-differentiated follicular thyroid carcinomas, 
MTC is more likely to present with metastatic cervical 
adenopathy (50%) at the time of initial presentation (Sherman 
2003); early lymphatic spread to the perithyroidal and pre-
tracheal lymph nodes is not uncommon. Similarly, more 
extensive lymphatic spread commonly involves the lateral 
compartments, including the jugular and supraclavicular 
nodes. In a recent report by Machens et al tumor multifocality 
was found to be an independent risk factor of lymph node 
metastasis on top of primary tumor size (Machens et al 2007). 
The hereditary form of MTC – those carcinomas showing 
an autosomal dominant pattern of transmission and arising 
as part of multiple endocrine neoplasia (MEN) syndrome 
types 2A or 2B or familial MTC (FMTC) – is characterized 
by the early onset of multifocal and bilateral disease (Scollo 
et al 2003). The sporadic form, accounting for nearly 70% 
of MTC cases, has been shown to have palpable cervical 
adenopathy in 30%–60% of cases (Chong et al 1975; Rougier 
et al 1983; Saad et al 1984). Lymph node involvement is 
present in 10%–30% of tumors smaller than 10 mm (Beressi 
et al 1998; Gimm et al 1999) and is more frequent in patients 
with larger tumors (Machens et al 2007). For these reasons, 
total thyroidectomy and bilateral CLND is recommended for 
all MTC patients; moreover, ipsilateral MRND is advocated 
in cases of sporadic MTC with clinically evident cervical 
adenopathy, tumors larger than 10 mm in diameter, and 
involvement of the central neck compartment (Udelsman 
and Chen 1999; Scollo et al 2003; Shaha 1998; Kebebew 
and Clark 2000; Mazzaferri 1999).
Role of 131I adjuvant therapy
Near-total and total thyroidectomy followed by 131I ablation 
confers a distinct outcome advantage for PTC and FTC. 
There are multiple reasons for the use of adjuvant radioiodine 
ablation of residual thyroid tissue following thyroidectomy: 
(1) to destroy residual microscopic foci of disease; (2) to 
improve monitoring of recurrent or metastatic disease with 
131I scanning by eliminating uptake by normal thyroid tissue 
and improving the speciﬁ  city of the scan; and (3) to enhance 
the value of serum thyroglobulin measurements as a serum 
marker of recurrent disease (Sherman 2003). Signiﬁ  cant 
retrospective data from multiple large studies suggest that 131I 
ablation reduces long-term disease speciﬁ  c mortality in those 
patients whose primary tumors are 10 mm in diameter, 
are multicentric, or have capsular or soft-tissue invasion at Therapeutics and Clinical Risk Management 2008:4(5) 939
Multi-targeted approach in the treatment of thyroid cancer
presentation (Sherman 2003; Mazzaferri and Jhiang 1994; 
Taylor et al 1989; DeGroot et al 1990; Krisnamurthy and 
Blahd 1977; Wong et al 1990). Radioiodine ablation has 
been shown to be ineffective in patients with MTC and is 
only minimally effective in HCC; hence, it is not commonly 
used in these patients. Signiﬁ  cant complications of 131I abla-
tion include sialoadenitis, parotid gland pain, altered taste 
sensation, and dysphagia; these side effects are thought to 
result from radiation damage to the salivary glands, organs 
which have been shown to concentrate Na131I uptake via a 
carrier-mediated mechanism (Solans et al 2001). Though 
much less common, symptoms of lacrimal gland dysfunction 
(sicca syndrome), gastrointestinal symptoms, bone marrow 
suppression, and infertility have been reported (Solans et al 
2001; Sawka et al 2008a). Interestingly, though abnormali-
ties in testicular function are common within several months 
of a single therapeutic dose of radioactive iodine (RAI) 
(150 mCi), these biochemical abnormalities have been 
shown to resolve within 18 months (Sawka et al 2008a). In 
women treated with RAI for thyroid carcinoma, few adverse 
effects of RAI treatment related to gonadal function, fertility, 
or pregnancy are noted beyond 12 months, with the excep-
tion of a possible slightly earlier age of menopause (Sawka 
et al 2008b).
Thyroid-stimulating hormone
suppressive therapy
Experimental investigations have demonstrated that dif-
ferentiated thyroid cancer cells have membrane-bound 
thyroid-stimulating hormone (TSH) receptors and that the 
growth regulation of differentiated thyroid cancer depends 
upon TSH (Shiba et al 1989). Furthermore, TSH suppression 
by administration of thyroid hormone (L-thyroxine) has been 
shown to lower the recurrence rates FTC and PTC (Emerick 
et al 1993; Young et al 1980; Clark 1981; Mazzaferri 1987; 
Mazzaferri and Jhiang 1994) and improves survival after 
thyroidectomy (Schneider et al 1978; Fogelfeld et al 1998). 
Likewise, Clark and Gerend (1985) have shown that most 
HCCs have thyrotropin receptors; therefore, all patients with 
HCC are typically given postoperative thyrotropin suppres-
sion therapy (Yutan and Clark 2001). Currently, the appro-
priate degree of TSH suppression remains controversial. In 
a study of 141 patients who underwent hormone therapy 
following thyroidectomy, Pujol et al showed that relapse-free 
survival (RFS) was longer in patients with a greater degree of 
TSH suppression (all TSH values 0.05 mU/L); furthermore, 
multivariate analysis that included TSH levels, age, sex, his-
tology, and tumor node metastases stage showed that TSH 
levels predicted RFS independently of other variables (Pujol 
et al 1996). At our institution, we attempt to maintain TSH 
levels lower than 0.1mU/L and aim for undetectable levels. 
Historically, adverse clinical outcomes attributed to pro-
longed L-thyroxine suppressive therapy have included bone 
and cardiac disease (Burmeister 1994; Paloyan et al 1998; 
Bauer 1997); however, recent data suggest that patients with 
well-differentiated thyroid carcinoma are not at increased risk 
of developing low bone mass nor have a higher prevalence of 
vertebral fracture when treated with relatively low doses of 
L-thyroxine (Heijckmann et al 2005).
Molecular pathogenesis
and cytogenetics
Although most thyroid carcinomas are relatively indolent, 
there have been no signiﬁ  cant improvements in survival over 
the last two decades. In fact, the trend in US cancer mortality 
with associated annual percentage change (APC) for cancer 
of the thyroid is disturbing; while an average 3% decrease in 
mortality from thyroid cancer was seen in males and females 
from 1975–1985, such a decrease has been absent in either 
gender since 1985 (NCI 2008). More intriguing, Surveillance 
Epidemiology and End Results (SEER) data indicate a 6.2% 
increased incidence of thyroid cancer during the same two 
decades (NCI 2008). Clearly, insight into the molecular 
pathogenesis of HCC, MTC, ATC, and other aggressive 
forms of thyroid cancer may lead to the development of more 
targeted therapies in the future.
Fortunately, the molecular basis of well-differentiated 
thyroid carcinoma, MTC, and anaplastic thyroid cancer is 
currently under investigation. With the application of current 
molecular techniques, nearly two decades of research have 
begun to elucidate critical genetic pathways involved in the 
development of speciﬁ  c thyroid tumor types. In particular, 
chromosomal inversions or translocations causing mutations 
in the RET proto-oncogene may play an important role in 
approximately 40% of patients with PTC (Vidal et al 2005; 
Carlomagno et al 2002). Likewise, mutations that activate 
RET activity can lead to several hereditary cancer syndromes, 
including MEN types 2A and 2B and FMTC. Some studies 
suggest that differentiated thyroid carcinoma cell invasion 
is regulated through epidermal growth factor receptor-
dependent (EGFR) activation of matrix metalloproteinases 
(Yeh et al 2006). Anaplastic thyroid carcinoma is postulated 
to develop secondary to dedifferentiation from a more dif-
ferentiated tumor and has been associated with the loss of the 
p53 tumor suppressor protein (Sherman 2003; Moretti et al 
1997). Many of these ﬁ  ndings have paved the way for the Therapeutics and Clinical Risk Management 2008:4(5) 940
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development of phase II/III clinical trials, several of which 
may be found in Table 1. Fortunately, the importance of these 
genetic pathways, as well as a myriad of others, continue to 
be described today.
The RET receptor tyrosine kinase (RTK)
The RET gene encodes a 120-kDa transmembrane tyrosine 
kinase that functions as a receptor for the glial-derived 
neurotrophic factor (GDNF) family of growth factors (Manie 
et al 2001). Mutations in the RET proto-oncogene have been 
implicated in patients with hereditary MTC associated with 
MEN types 2A and 2B and familial MTC (FMTC). Like-
wise, nearly 40% of patients with PTC have rearrangements 
of the RET gene that join the promoter and NH2-terminal 
domains of unrelated genes to the COOH-terminal fragment 
of RET (Vidal et al 2005). The cumulative result of the point 
Table 1 National Cancer Institute/US National Institutes of Health list of clinical trials now accepting participants
Clinical trial title Phase Type Status Age Sponsor
1.   Effect of Lithium Carbonate on Low-Dose Radioiodine 
Therapy in Early Thyroid Cancer
II Treatment Active 16 and over NIDDK
2.   Safety and Efﬁ  cacy Study of In-111 Pentetreotide to 
Treat Neuroendocrine Tumors
III Treatment Active 18 and over Other
3.   Clinical and Translational Study of MK-0646 in Patients 
With Metastatic Neuroendocrine Tumors (NET)
II Treatment Active 18 and over Other
4.   Avastin (Bevacizumab) and RAD001 (Everolimus) in 
Advanced Low or Intermediate Grade Neuroendocrine 
Carcinoma
II Treatment Active 18 and over Other
5.   An Initial Study of Lithium in Patients With Medullary 
Thyroid Cancer
NS Treatment Active 18 and over Other
6. Thyroid Cancer and Sunitinib II Treatment Active 18 and over Other
7.   Phase 2 Study Of AG-013736 In Patients With 
Doxorubicin-Refractory Or Intolerant Thyroid Cancer
II Treatment Active 18 and over Pharmaceutical/Industry
8.   Efﬁ  cacy and Safety of Lanreotide Autogel in 
Tumour Stabilization of Patients With Progressive 
Neuroendocrine Tumours
II Treatment Active 18 and over Pharmaceutical/Industry
9.   Phase II Two-Step Radioimmunotherapy Clinical Study
in Medullary Thyroid Carcinoma
II Treatment Active 18 to 75 Other
10.   A Phase I Study of BMS-690514 in Patients With 
Advanced or Metastatic Solid Tumors
I Treatment Active 18 and over Pharmaceutical/Industry
11.   Sorafenib in Treating Patients With Advanced 
Anaplastic Thyroid Cancer
II Treatment Active 18 and over NCI
12.  Lithium for Low-Grade Neuroendocrine Tumors II Treatment Active 18 and over NCI, Other
13.   The Safety and Efﬁ  cacy of CPTK787/ZK222584 in 
Patients With Metastatic Neuroendocrine Tumors
II Treatment Active 18 and over Other
14.   A Phase 1/2 Dose Finding Study of an Experimental 
New Drug CS7017, an Oral PPARγ Agonist Taken by 
Mouth Twice Daily in Combination With Paclitaxel 
Chemotherapy Administered Every Three Weeks by 
Venous Infusion by Patients With Anaplastic Thyroid 
Cancer
I, II Treatment Active 18 and over Pharmaceutical/Industry
15.   Efﬁ  cacy and Safety of Zactima™ in Patients With Meta-
static Papillary or Follicular Thyroid Cancer
II Treatment Active 18 and over Pharmaceutical/Industry
16.   Boronophenylalanine-Fructose Complex (BPA-F) and/
or Sodium Borocaptate (BSH) Followed By Surgery in 
Treating Patients With Thyroid Cancer, Head and Neck 
Cancer, or Liver Metastases
I Treatment Active 18 and over Other
17.   Irinotecan in Treating Patients With Metastatic or 
Inoperable Thyroid Cancer
II Treatment Active 18 and over NCI
18.   17-AAG in Treating Patients With Inoperable 
Locoregionally Advanced or Metastatic Thyroid Cancer
II Treatment Active 18 and over NCI
(Continued)Therapeutics and Clinical Risk Management 2008:4(5) 941
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mutations associated with MEN 2A and 2B and FMTC and 
the chromosomal rearrangements associated with PTC is 
activation of the RET receptor tyrosine kinase (RTK).
While MTC tends to be a slow-growing tumor primarily 
treated with surgical resection, it also frequently metastasizes 
to the liver and regional lymph nodes, precluding patients 
from a curative resection. Clearly, there is a great need for 
novel therapeutic and palliative strategies to treat these 
patients with metastatic MTC. RTK inhibitors are likely to 
be beneﬁ  cial for patients with hereditary MTC, where cur-
rently there are no effective chemotherapy or radiotherapy 
options.
ZD6474 (vandetanib) is a low-molecular-weight tyro-
sine kinase inhibitor that has demonstrated potent and 
selective inhibition of RTK in vitro (Carlomagno et al 
2002; Wedge et al 2002). In additional pre-clinical studies, 
Table 1 (Continued)
Clinical trial title Phase Type Status Age Sponsor
19.   Pazopanib in Treating Patients With Advanced Thyroid 
Cancer
II Biomarker/
Laboratory 
Analysis, 
Treatment
Active 18 and over NCI
20.   AZD6244 in Treating Patients With Papillary Thyroid 
Cancer That Did Not Respond to Radioactive Iodine
II Biomarker/
Laboratory 
Analysis, 
Treatment
Active 18 and over NCI
21.   FR901228 in Treating Patients With Recurrent and/or 
Metastatic Thyroid Cancer That Has Not Responded 
to Radioactive Iodine
II Treatment Active 18 and over NCI
22.   FR901228 in Treating Patients With Refractory Thyroid 
Cancer or Other Advanced Cancer
I Treatment Active 18 and over NCI
23.   Vandetanib in Treating Young Patients With Medullary 
Thyroid Cancer
II Biomarker/
Laboratory 
Analysis, 
Treatment
Active 5 to 18 NCI
24.   Sorafenib in Treating Patients With Metastatic, Locally 
Advanced, or Recurrent Medullary Thyroid Cancer
II Biomarker/
Laboratory 
Analysis, 
Treatment
Active 18 and over NCI
25.   Study of Combretastatin and Paclitaxel/Carboplatin
in the Treatment of Anaplastic Thyroid Cancer
III Treatment Active 18 and over Pharmaceutical/Industry
26.   Efﬁ  cacy Study of Sorafenib and Cyclophosphamide
to Treat Neuroendocrine Tumors
II Treatment Active 18 and over Other
27.   Sunitinib in Treating Patients With Thyroid Cancer 
That Did Not Respond to Iodine I 131 and Cannot Be 
Removed by Surgery
II Treatment Active 18 and over NCI
28.   Rosiglitazone in Treating Patients With Locoregionally 
Extensive or Metastatic Thyroid Cancer
II Treatment Active 18 and over Pharmaceutical/Industry, 
NCI
29.   Lenalidomide in Treating Patients With Metastatic Thyroid 
Cancer That Has Not Responded to Radioactive Iodine and 
Cannot Be Removed By Surgery
II Biomarker/
Laboratory 
Analysis, 
Treatment
Active 18 and over Pharmaceutical/Industry, 
Other
30.   Trial Evaluating Gleevec in Patients With Anaplastic Thyroid 
Carcinoma
II Treatment Active 18 and over Other
31.   Sorafenib in Treating Patients With Metastatic or 
Unresectable Resistant Thyroid Cancer
II Biomarker/
Laboratory 
Analysis, 
Treatment
Active NS NCI
32.   Valproic Acid (Depakote ER) in Patients With Advanced 
Thyroid Cancer
II Treatment Active 18 and over NCI, Other
Abbreviations: NS, not speciﬁ  ed; NCI, national cancer institute; NIDDK, national institute of diabetes and digestive and kidney diseases.Therapeutics and Clinical Risk Management 2008:4(5) 942
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Carlomagno et al (2005) have shown that ZD6474 blocks 
in vivo phosphorylation and signaling of the RET/PTC3 
and RET/MEN2B oncoproteins, inhibits the proliferative 
autonomy of RET/PTC3-transformed cells, and prevents 
the growth of two human PTC cell lines that carry spontane-
ous RET/PTC1 rearrangements. Based on phase I studies, 
ZD6474 was generally well tolerated at doses 300 mg/day 
and adverse events were generally mild and limited by dose 
adjustment. The most common monotherapy-related adverse 
outcomes included diarrhea, asymptomatic QTc prolonga-
tion, and a skin rash (Holden et al 2005; Tamura et al 2006). 
Currently, promising data in patients with MTC have led 
to ZD6474 being assigned orphan drug designation by the 
US Food and Drug Administration. These data are based on 
studies in which ZD6474 has demonstrated clinical activity 
in a single-arm Phase II study in 30 patients with metastatic 
hereditary MTC (Wells et al 2007). Concomitantly, an 
international, randomized, placebo-controlled phase II study 
of ZD6474 monotherapy in metastatic MTC is currently 
recruiting patients.
In addition to ZD6474, several other novel RTK inhibitors, 
sorafenib and sunitinib, for example, are under investigation 
for treatment of RET-dependent thyroid carcinomas. Utiliz-
ing an orthotopic anaplastic thyroid carcinoma xenograft 
model in nude mice, Kim et al have shown that sorafenib, a 
multikinase inhibitor of RTK, VEGFR, and BRAF kinase, 
inhibits proliferation of ATC cell lines and inhibits tumor 
angiogenesis via induction of endothelial apoptosis (Kim et al 
2007). Similarly, the orally administered multitarget tyrosine 
kinase inhibitor, SU11248 (sunitinib), has been shown to be 
a novel potent inhibitor of thyroid oncogenic RET/papillary 
thyroid cancer kinases (Kim et al 2006).
EGFR as a therapeutic target
in human thyroid carcinoma
Epidermal growth factor (EGF) is a 6-kDa polypeptide which 
has been shown to stimulate the proliferation of normal and 
malignant thyroid cells and inhibit cellular differentiation 
Hoelting et al 1994). Overexpression of the EGF receptor 
(EGFR), a transmembrane 170-kDa glycoprotein tyrosine 
kinase, is frequently detected in thyroid carcinomas, and 
though controversial (Mitsiades et al 2006), this pathway 
has been proposed to be important for thyroid carcinoma 
proliferation and metastasis. Recent studies with geﬁ  tinib 
and erlotinib, well-known EGFR kinase inhibitors, have 
resulted in objective responses in patients with non-small 
cell lung cancers (NSCLC), tumors in which EGFR is also 
frequently overexpressed. This has led some to believe that 
novel therapeutic compounds targeting the EGFR pathway 
may have future palliative and therapeutic potential in 
patients with refractory or metastatic thyroid carcinomas. In 
fact, the aforementioned compound ZD6474 is, in addition 
to its role in RTK inhibition, a potent and selective inhibitor 
of vascular endothelial growth factor receptor (VEGFR) 
and EGFR. As above, this compound is currently in phase II 
clinical trials to measure its efﬁ  cacy and clinical impact in 
patients with hereditary MTC.
Interestingly, many of the novel RTK inhibitors, 
ZD6474, sorafenib, and sunitinib, for example, appear to 
non-speciﬁ  cally inhibit multiple signaling pathways critical 
in thyroid carcinogenesis, suggesting a potential synergistic 
effect to these novel drugs; however, the question of whether 
this lack of speciﬁ  city will be advantageous or disadvanta-
geous in the long run for patients remains unanswered.
More recently, studies have demonstrated that differentiated 
thyroid cancer cell invasion in vivo is regulated through 
EGFR-dependent activation of matrix metalloproteinase 
(MMP)-2/gelatinase A (Yeh et al 2006). Undoubtedly, the 
role of MMP inhibitors as effective anti-tumor agents for the 
treatment of aggressive thyroid carcinomas is intriguing.
BRAF mutations in PTC
Kimura et al studied 124 snap frozen tumor samples, including 
78 papillary carcinomas, using DNA isolation and single-strand 
conformational polymorphism (SSCP) analyses (Kimura et al 
2003). Overall, 28 of 124 cancers demonstrated mutations in 
exon 15 of the B-type Raf kinase (BRAF) gene; all had the 
same thymine-to-adenine transversion at nucleotide 1796, 
resulting in a valine-to-glutamate substitution at residue 600 
(currently designated as V600E). More importantly, all of the 
BRAF V600E mutations were in papillary carcinomas (Kimura 
et al 2003). By contrast, all 46 of the follicular neoplasms 
were wild-type. Since this initial report, Xing has shown that 
the BRAF activating mutation is the most common genetic 
alteration in thyroid cancer (Xing 2005), occurring in 18% to 
87% of thyroid cancers (Trovisco et al 2006); importantly, the 
BRAFV600E mutation occurs in nearly 45% of sporadic cases of 
PTC (Xing 2005) and 24% of cases of anaplastic carcinoma 
(Salvatore et al 2006). Recently, Kebebew and colleagues 
sought to determine the association of BRAF mutations with 
indicators of poor prognosis for PTC and patient outcome 
in an attempt to determine whether BRAFV600E is associated 
with an aggressive tumor phenotype (Kebebew et al 2007). In 
patients with conventional PTC, patients with the BRAFV600E 
mutation were associated with a more aggressive tumor 
phenotype and were characterized by older age at the time of Therapeutics and Clinical Risk Management 2008:4(5) 943
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initial presentation, the presence of lymph node and/or distant 
metastases, higher TNM stage, and recurrent or persistent 
disease with a median follow-up of 6 years (Kebebew et al 
2007). Genetic analysis for BRAF mutations in patients with 
PTC may enable better prediction of those tumors associated 
with a poor prognosis and may be useful in selecting initial 
therapeutic modalities in these patients.
The raf-1/mitogen-regulated extracellular 
kinase (MEK)/extracellular regulated 
kinase (ERK) pathway in MTC
The raf-1/MEK/ERK pathway has long been recognized for 
its role in cancer biology. Although activation of this signaling 
pathway is commonly considered to be growth promoting in 
several cancers, in certain cell-speciﬁ  c subtypes, raf-1 acti-
vation results in growth suppression (Kunnimalaiyaan et al 
2007b). Speciﬁ  cally, activation of the raf-1 signaling pathway 
in MTC has been shown to lead to signiﬁ  cant morphologic dif-
ferentiation and growth reduction both in vitro and in a mouse 
xenograft TT model in vivo (Ravi et al 1998, 1999; Park et al 
2003; Vaccaro et al 2006). Similarly, we have shown that raf-1 
activation results in a reduction of the neuroendocrine tumor 
markers achaete-scute complex-like 1 (ASCL1), chromogranin 
A (CgA), and calcitonin in vitro (Park et al 2003; Kunnimalai-
yaan and Chen 2006; Chen et al 2005; Sippel et al 2003).
Until recently, the mechanism by which raf-1 pathway 
activation inhibits MTC cell growth was unclear; in fact, 
conﬂ  icting observations had been reported regarding the 
regulation of ERK1/2 in MTC cancer cells. Recent studies 
into the role of GSK-3β and its downstream relationship to 
Raf-1 have begun to elucidate the mechanisms responsible 
for growth inhibition in MTC cells.
Inactivation of glycogen synthase 
kinase- 3β (GSK-3β) in MTC
GSK-3β is a multifunctional serine/threonine protein kinase 
that plays an important role in cellular metabolism, cell 
fate determination, proliferation, and survival (Hardt and 
Sadoshima 2002; Harwood et al 1995). The activity of this 
kinase is inhibited by phosphorylation of a single serine residue 
(Ser9). Thus, unlike other kinases, GSK-3β is highly active 
when non-phosphorylated (in unstimulated cells), and becomes 
inactivated (phosphorylated) in response to signaling cascades, 
including the raf-1/MEK/ERK pathway (Cohen and Frame 
2001). At our institution, Kunnimalaiyaan et al (2007b) found 
that raf-1 activation in human MTC cells (TT cells) results in 
phosphorylation of GSK-3β (Kunnimalaiyaan et al 2007b). 
Furthermore, inactivation of GSK-3β by phosphorylation 
results in MTC growth inhibition both in vitro and in vivo. 
Inactivation of GSK-3β in TT cells with well known GSK-3β 
inhibitors such as lithium chloride (LiCl) and SB216763 is 
associated with a signiﬁ  cant decrease in neuroendocrine mark-
ers such as human-achaete-scute complex-like 1 (ASCL1) 
and chromogranin A (CgA). LiCl has been utilized clinically 
for more than ﬁ  fty years as an adjunctive psychiatric medica-
tion for the treatment of bipolar disorder and has shown only 
minimal adverse side effects. As such, the efﬁ  cacy of LiCl 
therapy in patients with MTC is currently being investigated 
at our institution in phase II clinical trials.
Overexpression of the Notch1 
intracellular domain in MTC
Notch1 is a multifunctional transmembrane receptor that 
regulates cellular differentiation, proliferation, and survival 
(Kadesh 2004; Maillard and Pear 2003; Yoon and Gaiano 
2005). Binding of any one of the Notch ligands (Delta1 (DLL-
1) or Jagged1 (JAG-1), for example) promotes a sequence of 
proteolytic cleavages resulting in the activated Notch intracel-
lular domain (NICD). The active NICD then translocates to the 
nucleus and binds with the DNA-binding protein complex CSL 
(CBF1, Su (H), and LAG-1), resulting in the transcriptional 
activation of target genes such as hairy enhancer of split-1 
(HES-1) (Kunnimalaiyaan et al 2007a). In human cancer cells, 
Notch1 has a dual role as either a tumor suppressor or an onco-
gene. It has been shown that Notch1 is upregulated in many 
types of cancer, including pancreatic cancer, colon cancer, 
non-small cell cancer, cervical cancer, renal cell carcinoma, 
and several lymphomas. It has been suggested that expression 
of Notch1 signaling prevents cellular differentiation and inhib-
its apoptosis in certain cancers. Conversely, Notch1 signaling 
is very minimal or absent in prostate cancer and NETs such 
as small-cell lung cancer (SCLC), pancreatic carcinoid, and 
MTC (Kunnimalaiyaan and Chen 2007). These apparent but 
paradoxical functions clearly indicate that the role of Notch 
signaling is dependent on its cellular context.
Using a doxycycline-inducible NICD in MTC cells 
(TT cells), we have recently shown that overexpression of 
Notch1 in MTC cells – Notch1 signaling is normally absent 
in MTC cells – results in a dose-dependent reduction in NE 
tumor markers and growth (Kunnimalaiyaan et al 2006, 
2007a; Kunnimalaiyaan and Chen 2007). These ﬁ  ndings 
indicate that identiﬁ  cation of compounds capable of phar-
macologically activating the Notch1 signaling may have a 
therapeutic role in treating NE diseases caused by aberrant 
expression of ASCL1 and other hormones. In fact, our labo-
ratory has recently shown the histone deacetylase (HDAC) Therapeutics and Clinical Risk Management 2008:4(5) 944
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inhibitors valproic acid (VPA) and suberoyl bis-hydroxamic 
acid (SBHA) to be strong Notch1 activators in NE tumors, 
including MTC. Moreover, we have shown these compounds 
to limit growth and reduce neuroendocrine markers both in 
vitro and in vivo. The efﬁ  cacy of these HDAC inhibitors 
as part of a comprehensive therapy in patients with MTC 
is currently being investigated at our institution in ongoing 
phase II clinical trials.
Mutation of the p53 tumor
suppressor gene
The tumor suppressor gene, p53, plays a critical role in cell 
cycle control, DNA repair, and synthesis, apoptosis, and 
many other cellular processes. Though it is believed that 
nearly 50% of all human malignancies are due to inactivat-
ing mutations of the p53 tumor suppressor gene, the signiﬁ  -
cance of the p53 gene in thyroid carcinogenesis is less clear 
(Malaguarnera et al 2007). In a review of the International 
Agency for Research on Cancer (IARC) TP53 tumor sup-
pressor database, the largest comprehensive database of its 
kind in existence, Olivier et al showed inactivating mutations 
of the p53 gene have been found in only 10% of thyroid car-
cinomas and mainly in poorly differentiated and aggressive 
histotypes (Olivier et al 2002). Similarly, in a cohort of nearly 
100 patients, Saltman et al clearly demonstrated the presence 
of aberrant p53 expression in more aggressive phenotypes 
of thyroid carcinoma; the study demonstrated a gradual 
increase in p53 immunopositivity rate along the spectrum of 
thyroid carcinoma progression with a statistically signiﬁ  cant 
difference between well-differentiated PTC and anaplastic 
phenotypes (0% vs 31.8%, respectively; p  0.001) (Saltman 
et al 2006). Clearly, studies elucidating the role of inac-
tivating mechanisms in the early stages of thyroid cancer 
are needed to help facilitate a better understanding of the 
complex network of p53 family member isoforms and their 
role in thyroid carcinogenesis.
Conclusion
While constituting only 1% of solid organ malignancies 
(9% in women), thyroid carcinoma is the most common 
malignancy of the endocrine system. The majority of patients 
with well-differentiated thyroid carcinoma are cured with 
adequate surgical management; however, some thyroid 
malignancies such as MTC or poorly differentiated thyroid 
carcinomas frequently metastasize, precluding patients from 
a curative resection. As such, novel palliative and therapeutic 
strategies are needed for this patient population. This review 
is a summary of our standard treatment strategies for PTC, 
MTC, HCC, follicular cancers, and anaplastic carcinoma of 
the thyroid. In addition, we hope to shed some light on the 
molecular pathogenesis and cytogenetics of these cancers by 
providing information on the myriad cell signaling pathways 
currently under investigation. We acknowledge that while 
not entirely inclusive of all ongoing research, the above 
mentioned pathways appear signiﬁ  cant in the tumorigenesis 
of thyroid carcinoma.
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